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Abstract
A 26-year-old gravida 3 para 1+1 was referred for antenatal care. In her last pregnancy she had a early
spontaneous preterm delivery at 32 weeks and 2 days complicated by intra hepatic cholestasis of
pregnancy. She had a strong family history of ischemic heart and combined hyperlipidaemia. In view of
her past obstetric history a baseline liver function test and fasting bile acid assay was carried out.
Upto 21 week her Bile acids were normal but at 22 weeks her fasting bile acid assay increased to the
upper limit of normal (9 µmol/L).
Ursodeoxycholic acid was started from 28 weeks gestation on a dosage of 500 mg b.i.d., which was
subsequently increased to 500 mg t.d.s. at 32 weeks.
At 34 weeks she gave a history of occasional right upper quadrant abdominal pain and her
biochemistry revealed raised serum aspartate transaminase ,alanine transaminase, fasting serum
triglyceride and cholesterol levels 58 IU,79 IU/L,18.37 mmol/L and 25.7 mmol/L respectively. The
triglyceride level was too high to calculate the low density lipoprotein cholesterol. A diagnosis of
severe intrahepatic cholestasis of pregnancy in a patient with background familial combined
hyperlipidaemia was made. Ultrasound abdomen and cardiotocography was normal. She had normal
delivery. In cases of early onset cholestasis of pregnancy we suggest that lipid profiles are checked in
these patients to rule out hyperlipidaemia and its attendant short term and long-term risks. More
research will be required to ascertain if there is a link between these 2 disorders.
Introduction
We report a case of severe early onset reoccurring
intrahepatic cholestasis of pregnancy (ICP) in a patient
with exacerbation of familial combined hyperlipidaemia
(Fredrickson/WHO type V). To our knowledge this is the
first described case.
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aetiology occurring in 1/1000-10,000 pregnancies [1]. It
usually presents in the 3
rd trimester of pregnancy and
rarely in the second trimester before 25 weeks gestation. It
characteristically presents as pruritus initially of the palms
and soles mainly at night, progressively spreading to other
parts of the body and increasingly becoming more
persistent. The prevalence of jaundice varies from 17-
75% [1-3]. While perinatal mortality can be as high as
20%, maternal monitoring of fetal movement and
electronic fetal monitoring have been shown to be
unreliable in preventing foetal loss [4].
Case presentation
A 26-year-old (Caucasian British, gravida 3 para 1+1) was
referred to the Conquest Hospital, East Sussex at 8 weeks
gestation for antenatal care.
She had suffered an early miscarriage at 9 weeks gestation
with her first pregnancy and subsequently a spontaneous
preterm delivery at 32 weeks and 2 days with her following
pregnancy. That pregnancy had been complicated by
intrahepatic cholestasis of pregnancy (ICP).
She had a strong family history of ischemic heart disease.
On her maternal side, her grandfather had died of
myocardial infarction (MI) at the age of 61 years and
her uncle had an MI at the age of 45 years. On her
paternal side of the family, her uncle aged 41 years, had
suffered an acute coronary event. Her father aged
61 years, has combined hyperlipidaemia. She is a non-
smoker.
At her booking visit at 10 weeks gestation clinical
examination was unremarkable and her body mass index
was normal. In view of her past obstetric history a baseline
liver function test (LFT) and fasting bile acid assay (BA)
was carried out. Her alanine transaminase (ALT) was
slightly elevated 42 IU/L (3-31) otherwise her LFT and
fasting BA assay were within normal limits, bile acid =3
µmol/L (Normal limits 0-10). At her next appointment
(16 weeks gestation), she admitted to itching of her palms
and soles mainly at night. A repeat LFT was all within
normal limits as was the fasting BA, 6 µmol/L. She was
again seen 2 weeks later in the antenatal clinic at 18 weeks
gestation, her itching had worsened, and otherwise routine
antenatal checks were normal. Her fasting BA assay
remained normal 4 µmol/L, she was started on piriton
tablets and calamine lotion and given a further appoint-
ment at 20 weeks at which her symptoms persisted and the
fasting BA remained normal (6 µmol/L), as did her
management.
Subsequent fetal anomaly scan carried out at 21 weeks
gestation was normal.
At 22 weeks her fasting BA assay increased to the upper
limit of normal (9 µmol/L), her LFT remained normal and
in view of her persistent itching, it was recommended that
she started ursodeoxycholic acid (UDCA), but this was
declined. She continued on piriton tablets 4 mg 8 hourly.
A follow-up appointment was arranged for 24 weeks, at
this appointment she said that all was well, her latest
fasting BA assay was 5 µmol/L.
However she admitted feeling unwell, experiencing some
uterine contractions and reduced fetal movements at
26 weeks gestation. Routine examinations were normal.
Ultrasound fetal biometric measurements were consistent
with good growth and cardiotocography (CTG) tracing
was reactive with evidence of fetal activity. LFT, urea and
electrolytes were all within normal range. For the first time
in this pregnancy her fasting BA assay was slightly above
normal range (12µ mol/L). In view of her past obstetric
history, she was given 2 doses of 12 mg of betamethasone
intramuscular injections 24 hours apart. At 28 weeks
gestation she admitted to worsen of her itching mainly at
night, her fasting BA assay was 13 µmol/L and her LFT
remained normal. She was commenced on UDCA 500 mg
twice daily orally, vitamin K 10 mg daily and aqueous
menthol cream at night for relief of itching.
We decided to see her weekly for clinical review and
monitoring of her biochemistry. Her symptoms remained
unchanged over the following 3 weeks as did her
biochemistry notably her fasting BA assay 7, 1 and
7 µmol/L at 29, 30 and 31 weeks respectively.
Fetal growth ultrasound scan and CTG monitoring were
reassuring.
At 32 weeks gestation, she complained of worsening
pruritis, she noticed that her urine had become darker but
denied change in the colour of her faeces. Her serum BA
shotupto161µmol/L,whileherLFTremainednormal.The
decision was made to increase the UDCA to 500 mg t.d.s.
At 34 weeks she gave a history of occasional right upper
quadrant abdominal pain associated with vomiting
described as “soap-like”.O ne x a m i n a t i o ns h ew a s
anicteric, normotensive with vague upper right abdominal
tenderness. Her biochemistry revealed raised serum
aspartate transaminase (AST) and ALT 58 and 79IU/L
respectively. The blood sample was grossly lipaemic;
fasting serum triglyceride and cholesterol levels were
significantly raised 18.37 mmol/L and 25.7 mmol/L
respectively. The triglyceride level was too high to calculate
the low density lipoprotein cholesterol (LDLC). Her serum
amylase level was normal 17IU/L as was her thyroid
function test. Her fasting BA assay was raised; 134 µmol/L.
Upper abdominal ultrasounds scan revealed a normal liver
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calculi. Fetal wellbeing was confirmed by reactive CTG
and satisfactory growth on ultrasound scan.
A diagnosis of severe ICP in a patient with background
familial combined hyperlipidaemia was made. We
excluded acute fatty liver of pregnancy and closely
observed her for the onset of superimposed acute
pancreatitis in the presence of the hypertriglyceridaemia.
The patient was placed on reduced fat diet to less than
10%, increased fluid intake (3 Litres /24 hours), daily
serum amylase and lipid monitoring. We planned to
induce labour at 34 weeks and 3 days.
She presented at 34 weeks and 2 days in established labour
and following a 7-hour labour had a spontaneous vaginal
delivery of a live 2550 g male baby. Apgar scores were
5 @ 1 minute and 8 @5 minutes.
Her lipid profile was assessed on day 3, 5, 9 and 6 weeks
postpartum (Table 1).
Discussion
Physiological hyperlipidaemia of pregnancy consist pri-
marily of an increase in triglycerides, with a lesser degree of
a rise in cholesterol and phospholipids in pregnancy [5].
This physiological change is exacerbated in cases with
underlying familial hyperlipidaemia, with the attendant
risk of cholesterol gall stone formation and acute
pancreatitis secondary to the hypertriglyceridaemia.
Our patient presented with a known history of severe ICP
and a strong family history of familial combined hyperli-
pidaemia. She had never been diagnosed with hyperlipi-
daemia prior to this pregnancy. This is probably explained
by the absence of clinical features, such as tuberoeruptive
xanthoma or hepatomegaly. Her previous preterm delivery
at 32 weeks, a known complication of cholestasis of
pregnancy [6], may have predated the excessive increase in
serum level of triglycerides as to induce the lipaemic serum
which aroused suspicion in this case.
While the aetiology of cholestasis of pregnancy remains
unknown, studies of the pathogenesis indicate abnormal-
ities in the metabolism of sex hormones and BA.
Clinical studies support an aetiological role of estrogens.
These include the relationship between onset of disease
and high levels of oestrogen in the third trimester, higher
incidence of cholestasis of pregnancy in twin pregnancies
and similar symptoms in postnatal patients that use the
combined oral contraceptive pills for contraception [7].
Progesterone and BA metabolism in patients with choles-
tasis of pregnancy has been shown to differ from that of
healthy patients. While the overall progesterone synthesis
remains unchanged from that in normal pregnancies,
patients with ICP have been shown to have a higher
proportion of mono and disulfated metabolites of serum
progesterone. Glucuronidated metabolites are however
similar to that of healthy pregnant patients. This has led to
the suggestion of a selective defect in the biliary excretion
of sulphated progesterone metabolites into bile [8].
Cholesterol is essential in the production and integrity of
the cell membrane; it is also the precursor for the synthesis
of steroid hormones and BA. Exported cholesterol from
the liver and intestines exceed peripheral catabolism,
except during growth or tissue repair. The excess choles-
terol is returned to the liver (reverse cholesterol transport
process) and eliminated in bile as BAs and faecal sterols.
This process of BA synthesis is one of the predominant
means of excretion of excess cholesterol [9-10]. Up
regulation of BA synthesis by lipoprotein cholesterol
through increased cholesterol 7-alpha hydroxylase (the
rate determining step for conversion of cholesterol to BAs)
has been shown in in-vitro animal studies [11].
The role that the underlying familial combined hyperlipi-
daemia played in the severity of her ICP remains unclear.
We suspect that while she probably had a genetic
predisposition to ICP [7], her excessive circulating
cholesterol could have been an aggravating factor.
UDCA, a hydrophilic BA was started from 28 weeks
gestation on a dosage of 500 mg bd, which was
subsequentlyincreasedto500mgtdsat32weeksfollowing
a sudden steep rise in serum BA level to 161 µmol/L and
finally peaked at 207 µmol/L at 34 weeks (Figure 1). While
therehavebeensomeencouragingreportsfromsomesmall
studies, mainly in the improvement of BA levels and LFT,
meta-analysis of the use of UDCA have failed to show
significant benefits in the use of this medication for the
persistent alleviation of pruritus [12].
In the presence of the patient's underlying hyperlipidae-
mia, early management with low fat diet would have
improved her lipid state [13] reducing the attendant risk of
acute intrapartum pancreatitis that is associated with a
maternal mortality as high as 20%, which was a real
concern in our case [14]. We also suggest that improved
lipid profile may have improved our control of the ICP.
Table 1. Postnatal lipid profile
Post-op (day)/ weeks Cholesterol (mmol/L) Triglyceride (mmol/L)
0 22.30 14.97
3 19.0 15.78
5 17.30 15.28
9 13.40 13.89
6 weeks 8.10 3.97
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In cases of early onset cholestasis of pregnancy we suggest
that lipid profiles are checked in these patients to rule out
hyperlipidaemia and its attendant short term and long-
term risks. More research will be required to ascertain if
there is a link between these 2 disorders.
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Figure 1. Trend of bile acids (umol/L) levels at different
gestations. Ursodeoxycholic acid 500 mg bd from 28 weeks
gestation, increased to tds from 32 weeks gestation.
Page 4 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:8679 http://casesjournal.com/casesjournal/article/view/8679